Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 8Colorectal Neoplasms 6Neoplasms by Site 4Digestive System Neoplasms 4Pancreatic Neoplasms 3Neoplasms, Glandular and Epithelial 3Digestive System Diseases 3Pancreatic Diseases 2Neoplasms by Histologic Type 2Endocrine Gland Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Thymus Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Neoplasms 1Rectal Diseases 1Previously Treated Metastatic Colorectal Cancer 1Pancreatic cancer, adult 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intestinal Neoplasms 1Intestinal Diseases 1

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 21Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × napabucasin × Clear all
NCT02315534 2023-11-15

A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
34 enrolled 18 charts
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡